Stem | Stem Cell Therapeutics Corp. Announces Funding Of The Traumatic Brain Injury (TBI) Clinical Study And Issuance Of ...

CALGARY, ALBERTA--(Marketwire - Aug. 30, 2010) - Stem Cell Therapeutics Corp. ("SCT" or the "Company") (TSX VENTURE:SSS) wishes to publicize budgetary consent of the SCT-sponsored investigator-lead Phase IIa investigate entitled "A Phase IIa, Single Center, Open Label Study to Characterize the Safety of Human Chorionic Gonadotrophin (hCG) and Epoeitin Alpha (EPO) in Traumatic Brain Injury". After vital discussions between administration and the Board of Directors a preference was done to go deliver with the TBI clinical study. SCT will supply the appropriation necessary to full the the number enrolled of 10 TBI patients in a singular core open tag study, lead by Dr. David Zygun, to typify the safety of hCG and EPO in dire brain injury. A array of efficiency endpoints are segment of the hearing pattern to be able to access assorted aspects of neurological status.

Dr. Alan Moore, President and CEO of SCT mentioned "We are vehement to account this study, that is a poignant milestone, and demonstrates the Company's undertaking to the enrichment of our programs. This is an critical step for SCT as you pierce deliver and highlights our loyalty to successful in the biotechnology area. We are in the routine of evaluating all our programs and outline to make announcements as decisions are made."

The Company moreover wishes to publicize the distribution of batch options to the directors of the Company. SCT has released an total of 1,550,000 batch options to 3 of the Company's Board of Directors at an exercise cost of C$0.10 per share. These options will run out no after that than Aug 27, 2015 theme to germane vesting provisions. These options were awarded in accommodations with the Company's Stock Option Plan.

About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a open biotechnology firm (TSX VENTURE:SSS) focused on the growth and commercialization of drug-based therapies to treat middle nervous system diseases. SCT is a personality in the growth of therapies that implement drug to kindle a patient's own proprietor branch cells. The Company's programs target to correct brain and haughtiness function mislaid due to illness or injury. The Company's endless obvious portfolio of owned and protected egghead skill supports the prospective enlargement in to future clinical programs in countless neurological diseases such as dire brain injury, multi-part sclerosis, Huntington's disease, Alzheimer's disease, and ALS.

These bonds have not been purebred beneath the United States Securities Act of 1933, as amended, or the bonds laws of any state, and might not be offering or sole inside of the United States or to, or is to account or gain of U.S. persons unless an germane grant from U.S. registration mandate is available.

Except for chronological information, this press let go might enclose forward-looking statements, that simulate the Company's stream expectancy concerning future events. These forward-looking statements engage chance and uncertainties, that might result in but are not paltry to, varying marketplace conditions, the successful and timely finishing of clinical studies, the investiture of corporate alliances, the effect of aggressive products and pricing, new product development, uncertainties connected to the regulatory consent routine and other risks minute from time to time in the Company's continuing quarterly and annual reporting.

   .. Get More Details Now! ...